$GFLT
GenFlat Holdings, Inc.

2022 Q4 Form 10-Q Financial Statement

#000165495422013685 Filed on October 13, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2022 Q2
Revenue $0.00 $0.00 $1.884K
YoY Change -100.0% -100.0% -70.6%
Cost Of Revenue $1.884K
YoY Change -70.6%
Gross Profit $0.00
YoY Change
Gross Profit Margin 0.0%
Selling, General & Admin $33.04K $29.17K $65.41K
YoY Change -84.83% -83.74%
% of Gross Profit
Research & Development $137.2K
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $33.04K $29.17K $65.41K
YoY Change -84.84% -83.74% -81.12%
Operating Profit -$33.04K -$29.17K -$63.53K
YoY Change -83.85% -82.86% -81.31%
Interest Expense $295.00 $1.006K $6.740K
YoY Change -96.55% -88.15% -86.52%
% of Operating Profit
Other Income/Expense, Net -$173.00 -$3.410K $10.57K
YoY Change -96.89% -37.64% -2475.28%
Pretax Income -$33.21K -$32.58K -$52.96K
YoY Change -84.19% -81.45%
Income Tax
% Of Pretax Income
Net Earnings -$33.21K -$32.58K -$52.96K
YoY Change -84.19% -81.45% -84.44%
Net Earnings / Revenue -2810.93%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 21.30M shares 20.85M shares
Diluted Shares Outstanding 21.03M shares 20.85M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.23K $13.08K $25.33K
YoY Change -18.52% -87.08%
Cash & Equivalents $12.23K $13.08K $25.33K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $127.3K $136.3K $156.7K
YoY Change -24.49% -55.57%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $127.3K $136.3K $156.7K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $127.3K $136.3K $156.7K
YoY Change -87.75% -88.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $74.80K $76.29K $111.8K
YoY Change -12.23% -3.56%
Accrued Expenses $6.113K $11.76K $2.891K
YoY Change -80.73% -65.36%
Deferred Revenue
YoY Change
Short-Term Debt $69.87K $51.17K $250.0K
YoY Change -78.5% -82.94%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $150.8K $139.2K $364.7K
YoY Change -66.69% -67.2%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $150.8K $139.2K $364.7K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $150.8K $139.2K $364.7K
YoY Change -66.69% -67.36%
SHAREHOLDERS EQUITY
Retained Earnings -$3.418M -$3.385M -$3.353M
YoY Change 44.02% 56.47%
Common Stock $21.30K $21.30K $20.85K
YoY Change 2.16% 2.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$23.51K -$2.940K -$208.0K
YoY Change
Total Liabilities & Shareholders Equity $127.3K $136.3K $156.7K
YoY Change -87.75% -88.44%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2022 Q2
OPERATING ACTIVITIES
Net Income -$33.21K -$32.58K -$52.96K
YoY Change -84.19% -81.45% -84.44%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$16.02K $4.580K -$33.86K
YoY Change -86.21% -103.82% 50.06%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $8.170K $8.170K $8.170K
YoY Change 63.4% -104.09%
Cash From Investing Activities $8.170K $8.170K $8.172K
YoY Change 63.4% -104.09% -104.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.000K -25.00K $25.00K
YoY Change -72.0% -106.47% -89.15%
NET CHANGE
Cash From Operating Activities -16.02K 4.580K -$33.86K
Cash From Investing Activities 8.170K 8.170K $8.172K
Cash From Financing Activities 7.000K -25.00K $25.00K
Net Change In Cash -850.0 -12.25K -$684.00
YoY Change -99.01% -118.52% -108.7%
FREE CASH FLOW
Cash From Operating Activities -$16.02K $4.580K -$33.86K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
336935 usd
CY2022Q3 us-gaap Liabilities
Liabilities
139227 usd
CY2022Q1 us-gaap Liabilities
Liabilities
336935 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3385220 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-2940 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
136287 usd
CY2022Q3 us-gaap Revenues
Revenues
0 usd
CY2021Q3 us-gaap Revenues
Revenues
9245 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--02-28
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
139227 usd
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
dei Entity Central Index Key
EntityCentralIndexKey
0001796949
dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-08-31
dei Document Transition Report
DocumentTransitionReport
false
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21303000 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20853000 shares
CY2021Q2 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
50000 usd
CY2022Q2 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
225000 usd
CY2021Q2 us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
50000 usd
CY2022Q2 us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
225000 usd
CY2021Q2 us-gaap Debt Conversion Original Debt Interest Rate Of Debt
DebtConversionOriginalDebtInterestRateOfDebt
0.12 pure
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1580000 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.57
dei Document Type
DocumentType
10-Q
dei Entity File Number
EntityFileNumber
000-56214
dei Entity Registrant Name
EntityRegistrantName
Healthcare Business Resources Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3639946
dei Entity Address Address Line1
EntityAddressAddressLine1
718 Thompson Lane
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 108-273
dei Entity Address City Or Town
EntityAddressCityOrTown
Nashville
dei Entity Address State Or Province
EntityAddressStateOrProvince
TN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
37204
dei City Area Code
CityAreaCode
615
dei Local Phone Number
LocalPhoneNumber
856-5542
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21303000 shares
CY2022Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
51174 usd
CY2022Q1 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
0 usd
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20853000 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
21303 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3360977 usd
CY2022Q3 hbr Revenue
Revenue
0 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
94010 usd
CY2022Q3 us-gaap Professional Fees
ProfessionalFees
20646 usd
CY2021Q3 us-gaap Professional Fees
ProfessionalFees
85387 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
29168 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
179397 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29168 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-170152 usd
CY2022Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-2404 usd
CY2021Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
0 usd
CY2021Q3 us-gaap Interest Income Other
InterestIncomeOther
3024 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
1006 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
8492 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3410 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5468 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-32578 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-175620 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20853000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20853000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20853000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20853000 shares
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-171369 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
16326 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-208001 usd
CY2022Q3 hbr Common Shares Issued For Settlement Of Note Payable Related Party Amount
CommonSharesIssuedForSettlementOfNotePayableRelatedPartyAmount
225000 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
12639 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-32578 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-2940 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-36612 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30420 usd
CY2021Q2 hbr Common Shares And Warrants Issued For License Amount
CommonSharesAndWarrantsIssuedForLicenseAmount
38500 usd
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
252852 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-340414 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-55254 usd
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
55746 usd
CY2021Q3 hbr Common Shares And Warrants Issued For License Amount
CommonSharesAndWarrantsIssuedForLicenseAmount
857990 usd
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
69989 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-175620 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
752851 usd
us-gaap Net Income Loss
NetIncomeLoss
-516034 usd
us-gaap Share Based Compensation
ShareBasedCompensation
322841 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2228 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-14906 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
0 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-5556 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
0 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
2050 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
50711 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
81120 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-8513 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1231 usd
us-gaap Increase Decrease In Operating Assets
IncreaseDecreaseInOperatingAssets
0 usd
us-gaap Increase Decrease In Operating Assets
IncreaseDecreaseInOperatingAssets
1331 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29279 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-120013 usd
us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
0 usd
us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
-200000 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
16343 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16343 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-200000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
250000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
175000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
hbr Proceeds From Notes Payable Related Party
ProceedsFromNotesPayableRelatedParty
225000 usd
hbr Proceeds From Notes Payable Related Party
ProceedsFromNotesPayableRelatedParty
50000 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
50000 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
86166 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
386166 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-12936 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
66153 usd
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26013 usd
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35055 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13077 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
101208 usd
us-gaap Interest Paid
InterestPaid
5135 usd
us-gaap Interest Paid
InterestPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
38500 usd
us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
0 usd
us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
857990 usd
hbr Common Shares Issued For Settlement Of Note Payable Related Party
CommonSharesIssuedForSettlementOfNotePayableRelatedParty
225000 usd
hbr Common Shares Issued For Settlement Of Note Payable Related Party
CommonSharesIssuedForSettlementOfNotePayableRelatedParty
0 usd
us-gaap Securities Borrowed Credit Loss Expense Reversal
SecuritiesBorrowedCreditLossExpenseReversal
51174 usd
us-gaap Securities Borrowed Credit Loss Expense Reversal
SecuritiesBorrowedCreditLossExpenseReversal
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
14823 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2022Q3 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
123210 usd
CY2021Q3 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
25000 usd
CY2021Q3 us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
25000 usd
CY2021Q3 us-gaap Debt Instrument Description
DebtInstrumentDescription
Promissory Note will be due and payable two hundred seventy (270) days from the date the principal amount is received by the Company. Interest on the $25,000 Promissory Note will accrue at a rate of 12.0% per annum, beginning on the date the principal amount is received by the Company until the principal amount and all accrued but unpaid interest shall have been paid
CY2021Q3 us-gaap Debt Conversion Original Debt Interest Rate Of Debt
DebtConversionOriginalDebtInterestRateOfDebt
0.120 pure
CY2021Q3 us-gaap Unsecured Debt
UnsecuredDebt
25000 usd
CY2021Q3 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
150000 usd
CY2021Q3 us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
150000 usd
CY2021Q3 us-gaap Debt Instrument Description
DebtInstrumentDescription
Promissory Note will be due and payable two hundred seventy (270) days from the date the principal amount is received by the Company. Interest on the $150,000 Promissory Note will accrue at a rate of 12.0% per annum, beginning on the date the principal amount is received by the Company until the principal amount and all accrued but unpaid interest shall have been paid.
CY2021Q3 us-gaap Unsecured Debt
UnsecuredDebt
150000 usd
CY2021Q2 us-gaap Debt Instrument Description
DebtInstrumentDescription
principal amount of $50,000 (the “$50,000 Promissory Note”). The principal amount of $50,000 plus all interest under the $50,000 Promissory Note will be due and payable two hundred seventy (270) days from June 10, 2021. Interest on the $50,000 Promissory Note will accrue at a rate of 12.0% per annum, beginning on June 10, 2021, until the principal amount and all accrued but unpaid interest shall have been paid
CY2021Q2 us-gaap Unsecured Debt
UnsecuredDebt
50000 usd
CY2022Q2 us-gaap Debt Instrument Description
DebtInstrumentDescription
principal amount of $225,000 (the “$225,000 Promissory Note”). Stephen Epstein, the Company’s Chief Executive Officer, holds a Power of Attorney on behalf of Robert Epstein, who owns and controls RSET Investments QOZB, LLC. The principal amount of $225,000 plus all interest under the $225,000 Promissory Note will be due and payable on December 31, 2023. Interest on the $225,000 Promissory Note will accrue at the greater of rate of 2.0% per annum or the long-term adjusted applicable federal rates for the current month, beginning on the date the principal amount is received by the Company until the principal amount and all accrued but unpaid interest shall have been paid
CY2022Q2 us-gaap Unsecured Debt
UnsecuredDebt
225000 usd
CY2022Q2 hbr Promissory Note Converted
PromissoryNoteConverted
225000 usd
CY2022Q2 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
530 usd
CY2022Q2 hbr Promissory Note Converted Into Share
PromissoryNoteConvertedIntoShare
450000 shares
CY2022Q3 hbr Common Stock Issuance
CommonStockIssuance
450000 shares
CY2021Q4 hbr Consideration Amount Of Shares
ConsiderationAmountOfShares
10.00
CY2021Q4 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
32000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1580000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
1131482 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M14D
CY2022Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd

Files In Submission

Name View Source Status
0001654954-22-013685-index-headers.html Edgar Link pending
0001654954-22-013685-index.html Edgar Link pending
0001654954-22-013685.txt Edgar Link pending
0001654954-22-013685-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hbr-20220831.xsd Edgar Link pending
hbr_10q.htm Edgar Link pending
hbr_ex311.htm Edgar Link pending
hbr_ex312.htm Edgar Link pending
hbr_ex321.htm Edgar Link pending
hbr_ex322.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
hbr-20220831_cal.xml Edgar Link unprocessable
hbr-20220831_def.xml Edgar Link unprocessable
hbr-20220831_lab.xml Edgar Link unprocessable
hbr-20220831_pre.xml Edgar Link unprocessable
hbr_10q_htm.xml Edgar Link completed
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending